Everything below concerns dual agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-08. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
==== Affinity-based peptide biosensors ==== This kind of peptide biosensor rely on peptides that can selectively bind a target like proteins, Small molecules, or ions. These peptides often mimic natural binding motifs, receptor fragments, antibody epitopes or ligand domains. They are engineered via methods such as phage display or computational design to achieve high affinity and specificity for their targets. These biosensors are widely used for detecting proteins, toxins and biomarkers due to affinity. Because affinity interactions offer great selectivity without requiring enzymatic reactions, these biosensors are frequently utilized for detecting proteins, toxins, and biomarkers.
== External links == Anatomy photo: TermsCells&Tissues/connective/dense/dense1 - Comparative Organology at University of California, Davis - "Connective tissue, dense (LM, Low)" Histology at cytochemistry.net Overview at downstate.edu Archived 2016-03-03 at the Wayback Machine
Navy expeditions continued to be plagued by scurvy even while fresh (not jerked or tinned) meat was well known as a practical antiscorbutic among civilian whalers and explorers in the Arctic. In the latter half of the 19th century, there was greater recognition of the value of eating fresh meat as a means of avoiding or treating scurvy, but the lack of available game to hunt at high latitudes in winter meant it was not always a viable remedy. Criticism also focused on the fact that some of the men most affected by scurvy on Naval polar expeditions had been heavy drinkers, with suggestions that this predisposed them to the condition. Even cooking fresh meat did not destroy its antiscorbutic properties, especially as many cooking methods failed to bring all the meat to high temperature. The confusion is attributed to several factors:
Organometallic complexes analogous to uranocene are known also for other actinides, such as thorium, protactinium, neptunium, plutonium and americium. Molecular orbital theory predicts a stable "curocene" complex (η8-C8H8)2Cm, but it has not been reported experimentally yet. Formation of the complexes of the type Cm(n-C3H7-BTP)3 (BTP = 2,6-di(1,2,4-triazin-3-yl)pyridine), in solutions containing n-C3H7-BTP and Cm3+ ions has been confirmed by EXAFS. Some of these BTP-type complexes selectively interact with curium and thus are useful for separating it from lanthanides and another actinides. Dissolved Cm3+ ions bind with many organic compounds, such as hydroxamic acid, urea, fluorescein and adenosine triphosphate. Many of these compounds are related to biological activity of various microorganisms. The resulting complexes show strong yellow-orange emission under UV light excitation, which is convenient not only for their detection, but also for studying interactions between the Cm3+ ion and the ligands via changes in the half-life (of the order ~0.1 ms) and spectrum of the fluorescence. There are a few reports on biosorption of Cm3+ by bacteria and archaea, and in the laboratory both americium and curium were found to support the growth of methylotrophs.
Sources: en.wikipedia.org
Reumer, de Vos & Wibowo (2026) interpret Hemimachairodus zwierzyckii from the Pleistocene strata from Sangiran (Java, Indonesia) as a junior synonym of Homotherium latidens. Pérez et al. (2026) identify fossil material of lynxes from Serpenteko Leze de Mezkiritz pit (Navarre, Spain) as including remains of both the Iberian lynx and the Eurasian lynx, providing possible evidence of overlap of ranges of both species in northern Iberia around the Pleistocene–Holocene transition. Witt, Hotchner & Meachen (2026) report that postcranial remains of Miracinonyx trumani and cougars can be reliably differentiated on the basis of their postcranial remains, and identify fossils of M. trumani from new localities in United States and Mexico. Cassatt-Johnstone et al. (2026) determine Miracinonyx trumani to be the sister taxon of the cougar on the basis of data from high-coverage paleogenomes, identify three purported Pleistocene cougar individuals from Yukon (Canada) as individuals of M. trumani instead (extending known geographical range of the species), and report evidence of dietary differences between specimens of M. trumani from Yukon and Wyoming (United States). Lyubimov et al. (2026) report the discovery of fossil material of Acinonyx pardinensis from the Muhkai 2 site (Dagestan, Russia), representing the first record of the species in the northeastern Caucasus.
The greater sac, represented in red in the diagrams above. The lesser sac, represented in blue. The lesser sac is divided into two "omenta": The lesser omentum (or hepatogastric) is attached to the lesser curvature of the stomach and the liver. The greater omentum (or gastrocolic) hangs from the greater curvature of the stomach and loops down in front of the intestines before curving back upwards to attach to the transverse colon. In effect it is draped in front of the intestines like an apron and may serve as an insulating or protective layer. The mesentery is the part of the peritoneum through which most abdominal organs are attached to the abdominal wall and supplied with blood and lymph vessels and nerves.
=== Other antifreezes === Propylene glycol methyl ether is used as an antifreeze in diesel engines. It is more volatile than glycol. Once used for automotive antifreeze, glycerol has the advantage of being non-toxic, withstands relatively high temperatures, and is noncorrosive. It is not however used widely. Glycerol was historically used as an antifreeze for automotive applications before being replaced by ethylene glycol. Volkswagen introduced G13 (TL 774-G) antifreezes containing glycerol in 2008, marketed as better for the environment due to its low toxicity and reduced CO2 emissions. However, since 2018, they have moved on to G12EVO (TL 774-L) which no longer contains glycerol. Glycerol is mandated for use as an antifreeze in many sprinkler systems.
Open Chess Championship Peter Bacanovic (1984), Martha Stewart's stockbroker; involved in the ImClone scandal Annie Duke (1987), professional poker player Greg Giraldo (1987), stand-up comedian Anna Ivey (1994), admissions counsellor Chubby Hubby or Aun Koh (1996), Singaporean food and travel blogger Emily Drabinski (1997), librarian and educator, president of the American Library Association Tinsley Mortimer (1999), socialite and television personality Chloe Arnold (2002), Internationally acclaimed tap dancer La Carmina (2005), alternative blogger on Gothic and Japanese pop culture Alison Desir (2007), activist, runner John Cochran (2009), winner of Survivor: Caramoan Leeza Mangaldas (2011), Indian podcaster and sex educator Sara Ali Khan (2016), daughter of Indian actor, director Saif Ali Khan and actress Amrita Singh
Various types of alcohol were also used in ancient medical practices. One of the first uses was wine mixed with oil was a common remedy in the ancient world to cleanse wounds and assuage their pain as noted in the context of Alcohol in the Bible. The Sumerians used beer as an antiseptic along with the dressing of wounds, using up to 19 different types of beer. Other ancient Mesopotamian cultures, including the Sumerians and Akkadians used wine with sesame infusions, which were "purified and pulverized" before application along with the many beers. A medical prescription from Mesopotamia describes a method for healing wounds:
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.